SCHEMBL1275970

SCHEMBL1275970

CCCCCCC(=O)Oc1ccc(O)cc1

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
HSD17B3 P37058 6/20 0.57
NR5A1 Q13285 1/20 0.56
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
HTT P42858 1/20 0.50
HSD17B10 Q99714 1/20 0.50
LTA4H P09960 1/20 0.49
MIF P14174 1/20 0.48
BCL9 O00512 1/20 0.47
CTNNB1 P35222 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10942075 1.00 KMT2A (0.61) KMT2ASMN1; SMN2HSD17B3NR5A1NPC1
SCHEMBL17078358 1.00 KMT2A (0.61) KMT2ASMN1; SMN2HSD17B3NR5A1NPC1
SCHEMBL4600411 1.00 KMT2A (0.61) KMT2ASMN1; SMN2HSD17B3NR5A1NPC1
SCHEMBL2382553 1.00 KMT2A (0.61) KMT2ASMN1; SMN2HSD17B3NR5A1NPC1
SCHEMBL21382265 1.00 KMT2A (0.61) KMT2ASMN1; SMN2HSD17B3NR5A1NPC1
SCHEMBL7585387 1.00 KMT2A (0.61) KMT2ASMN1; SMN2HSD17B3NR5A1NPC1
SCHEMBL9724778 1.00 KMT2A (0.61) KMT2ASMN1; SMN2HSD17B3NR5A1NPC1
SCHEMBL1007275 1.00 KMT2A (0.61) KMT2ASMN1; SMN2HSD17B3NR5A1NPC1
Ammonia Solution, Strong SCHEMBL27940857 0.98 KMT2A (0.59) KMT2ASMN1; SMN2HSD17B3NR5A1NPC1
SCHEMBL28080413 0.98 KMT2A (0.59) KMT2ASMN1; SMN2HSD17B3NR5A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113646052-A Reversible thermal discoloration composition, reversible thermal discoloration microcapsule pigment encapsulating the reversible thermal discoloration composition, and writing instrument using the reversible thermal discoloration microcapsule pigment 百乐墨水株式会社 2021-11-12 CN disclosed
EP-2057222-B1 LIQUID PHOSPHITE BLENDS AS STABILIZERS ADDIVANT SWITZERLAND GMBH (CH) 2014-03-12 EP disclosed
US-8049041-B2 Phosphite stabilizer for lubricating base stocks and thermoplastic polymers CHEMTURA CORPORATION (US) 2011-11-01 US disclosed
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2011-05-05 US disclosed
EP-2294074-A1 PHOSPHITE STABILIZER FOR LUBRICATING BASE STOCKS AND THERMOPLASTIC POLYMERS Chemtura Corporation (US) 2011-03-16 EP disclosed
US-7888414-B2 Liquid phosphite blends as stabilizers CHEMTURA CORPORATION (US) 2011-02-15 US disclosed
US-20100048782-A1 Liquid phosphite blends as stabilizers SI GROUP, INC. 2010-02-25 US disclosed
US-20100016196-A1 PHOSPHITE STABILIZER FOR LUBRICATING BASE STOCKS AND THERMOPLASTIC POLYMERS CHEMTURA CORPORATION 2010-01-21 US disclosed
US-20100004363-A1 LIQUID PHOSPHITE BLENDS AS STABILIZERS CHEMTURA CORPORATION (US) 2010-01-07 US disclosed
WO-2009158078-A1 PHOSPHITE STABILIZER FOR LUBRICATING BASE STOCKS AND THERMOPLASTIC POLYMERS CHEMTURA CORPORATION (US) 2009-12-30 WO disclosed
WO-2009080722-A2 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2009-07-02 WO disclosed
EP-2057222-A2 LIQUID PHOSPHITE BLENDS AS STABILIZERS Chemtura USA Corporation (US) 2009-05-13 EP disclosed
WO-2007149143-A2 LIQUID PHOSPHITE BLENDS AS STABILIZERS CHEMTURA CORPORATION (US) 2007-12-27 WO disclosed
US-6919389-B2 Polymer compositions containing benzimidazole based stabilizer compounds CROMPTON CORPORATION (US) 2005-07-19 US disclosed
US-20040180995-A1 Polymer compositions containing benzimidazole based stabilizer compounds ADDIVANT USA, LLC 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004363-A1 LIQUID PHOSPHITE BLENDS AS STABILIZERS PHOSPHO1, PPA1, PLCG2 KMT2A 1101/4885SMN1; SMN2 231/4885HSD17B3 4880/4885
US-20100016196-A1 PHOSPHITE STABILIZER FOR LUBRICATING BASE STOCKS AND THERMOPLASTIC POLYMERS PHOSPHO1, PLCG2, PLPBP KMT2A 1446/4885SMN1; SMN2 128/4885HSD17B3 4419/4885
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AKR1C3, TPD52L2, HCCS KMT2A 2127/4885SMN1; SMN2 2869/4885HSD17B3 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.